Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers

References

• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26:5420-32; PMID:17694083; http://dx.doi.org/10.1038/sj.onc.1210610
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10:32-42; PMID:19065135; http://dx.doi.org/10.1038/nrg2485
   PubMed Web of Science ®Google Scholar
• Moser MA, Hagelkruys A, Seiser C. Transcription and beyond: the role of mammalian class I lysine deacetylases. Chromosoma 2014; 123:67-78; PMID:24170248; http://dx.doi.org/10.1007/s00412-013-0441-x
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012; 6:637-56; PMID:23141799; http://dx.doi.org/10.1016/j.molonc.2012.09.003
   PubMed Web of Science ®Google Scholar
• Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011; 8:2021-31; PMID:21899343; http://dx.doi.org/10.1021/mp200329f
   PubMed Web of Science ®Google Scholar
• Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 2010; 28(Suppl 1):S58-78; PMID:21132350; http://dx.doi.org/10.1007/s10637-010-9591-3
   PubMed Web of Science ®Google Scholar
• Petrella A, Fontanella B, Carratu A, Bizzarro V, Rodriquez M, Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev Med Chem 2011; 11:519-27; PMID:21561404; http://dx.doi.org/10.2174/138955711795843347
   PubMed Web of Science ®Google Scholar
• Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012; 4:1439-60; PMID:22857533; http://dx.doi.org/10.4155/fmc.12.80
   PubMed Web of Science ®Google Scholar
• Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001; 21:6470-83; PMID:11533236; http://dx.doi.org/10.1128/MCB.21.19.6470-6483.2001
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18:7176-84; PMID:9819404
   PubMed Web of Science ®Google Scholar
• Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59:2766-9; PMID:10383127
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008; 30:61-72; PMID:18406327; http://dx.doi.org/10.1016/j.molcel.2008.02.030
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Hiebert SW. Role for histone deacetylase 3 in maintenance of genome stability. Cell Cycle 2011; 10:727-8; PMID:21311228; http://dx.doi.org/10.4161/cc.10.5.14866
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010; 18:436-47; PMID:21075309; http://dx.doi.org/10.1016/j.ccr.2010.10.022
   PubMed Web of Science ®Google Scholar
• Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev 2008; 22:2639-44; PMID:18832068; http://dx.doi.org/10.1101/gad.484108
   PubMed Web of Science ®Google Scholar
• Sun Z, Feng D, Fang B, Mullican SE, You SH, Lim HW, Everett LJ, Nabel CS, Li Y, Selvakumaran V, et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol Cell 2013; 52:769-82; PMID:24268577; http://dx.doi.org/10.1016/j.molcel.2013.10.022
   PubMed Web of Science ®Google Scholar
• Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 2002; 21:2672-81; PMID:12032080; http://dx.doi.org/10.1093/emboj/21.11.2672
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007; 21:1790-802; PMID:17639084; http://dx.doi.org/10.1101/gad.1563807
   PubMed Web of Science ®Google Scholar
• Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13:324-31; PMID:17322895; http://dx.doi.org/10.1038/nm1552
   PubMed Web of Science ®Google Scholar
• Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459:55-60; PMID:19424149; http://dx.doi.org/10.1038/nature07925
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, Wurst W, Minucci S, Gottlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007; 67:9047-54; PMID:17909008; http://dx.doi.org/10.1158/0008-5472.CAN-07-0312
   PubMed Web of Science ®Google Scholar
• Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29:2586-97; PMID:20571512; http://dx.doi.org/10.1038/emboj.2010.136
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 2010; 24:455-69; PMID:20194438; http://dx.doi.org/10.1101/gad.552310
   PubMed Web of Science ®Google Scholar
• Jamaladdin S, Kelly RD, O'Regan L, Dovey OM, Hodson GE, Millard CJ, Portolano N, Fry AM, Schwabe JW, Cowley SM. Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells. Proc Natl Acad Sci U S A 2014; 111:9840-5; PMID:24958871; http://dx.doi.org/10.1073/pnas.1321330111
   PubMed Web of Science ®Google Scholar
• Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A 2009; 106:7751-5; PMID:19416910; http://dx.doi.org/10.1073/pnas.0903139106
   PubMed Web of Science ®Google Scholar
• He S, Khan DH, Winter S, Seiser C, Davie JR. Dynamic distribution of HDAC1 and HDAC2 during mitosis: association with F-actin. J Cell Physiol 2013; 228:1525-35; PMID:23280436; http://dx.doi.org/10.1002/jcp.24311
   PubMed Web of Science ®Google Scholar
• Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27:4784-95; PMID:17470557; http://dx.doi.org/10.1128/MCB.00494-07
   PubMed Web of Science ®Google Scholar
• Heideman MR, Wilting RH, Yanover E, Velds A, de Jong J, Kerkhoven RM, Jacobs H, Wessels LF, Dannenberg JH. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 2013; 121:2038-50; PMID:23327920; http://dx.doi.org/10.1182/blood-2012-08-450916
   PubMed Web of Science ®Google Scholar
• Winter M, Moser MA, Meunier D, Fischer C, Machat G, Mattes K, Lichtenberger BM, Brunmeir R, Weissmann S, Murko C, et al. Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis. EMBO J 2013; 32:3176-91; PMID:24240174; http://dx.doi.org/10.1038/emboj.2013.243
   PubMed Web of Science ®Google Scholar
• Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009; 23:1625-30; PMID:19605684; http://dx.doi.org/10.1101/gad.1809209
   PubMed Web of Science ®Google Scholar
• Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, Saitoh K, Komata M, Katou Y, Clark D, et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 2012; 489:313-7; PMID:22885700; http://dx.doi.org/10.1038/nature11316
   PubMed Web of Science ®Google Scholar
• Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, Jackson SP. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17:1144-51; PMID:20802485; http://dx.doi.org/10.1038/nsmb.1899
   PubMed Web of Science ®Google Scholar
• Sirbu BM, Couch FB, Feigerle JT, Bhaskara S, Hiebert SW, Cortez D. Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev 2011; 25:1320-7; PMID:21685366; http://dx.doi.org/10.1101/gad.2053211
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Jacques V, Rusche JR, Olson EN, Cairns BR, Chandrasekharan MB. Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression. Epigenetics Chromatin 2013; 6:27; PMID:23947532; http://dx.doi.org/10.1186/1756-8935-6-27
   PubMed Web of Science ®Google Scholar
• Milutinovic S, Zhuang Q, Szyf M. Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification. J Biol Chem 2002; 277:20974-8; PMID:11929879; http://dx.doi.org/10.1074/jbc.M202504200
   PubMed Web of Science ®Google Scholar
• Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008; 36:5678-94; PMID:18772227; http://dx.doi.org/10.1093/nar/gkn550
   PubMed Web of Science ®Google Scholar
• Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006; 311:844-7; PMID:16469925; http://dx.doi.org/10.1126/science.1124000
   PubMed Web of Science ®Google Scholar
• Clapier CR, Cairns BR. Regulation of ISWI involves inhibitory modules antagonized by nucleosomal epitopes. Nature 2012; 492:280-4; PMID:23143334; http://dx.doi.org/10.1038/nature11625
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102:83-7; PMID:21171509
   PubMedGoogle Scholar
• Foon KA, Takeshita K, Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Adv Hematol 2012; 2012:302570; PMID:22536253; http://dx.doi.org/10.1155/2012/302570
   PubMedGoogle Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505; PMID:22160081; http://dx.doi.org/10.1182/asheducation-2011.1.498
   PubMed Web of Science ®Google Scholar
• Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009; 113:5536-48; PMID:19307668; http://dx.doi.org/10.1182/blood-2008-12-193037
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis 2008; 41:95-9; PMID:18346918; http://dx.doi.org/10.1016/j.bcmd.2008.02.003
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Wang L, Polo JM, Dell'Oso T, Dierov J, Gaymes TJ, Rassool F, Carroll M, Melnick A. BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem 2008; 283:22565-72; PMID:18524763; http://dx.doi.org/10.1074/jbc.M803490200
   PubMed Web of Science ®Google Scholar
• Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 2000; 14:1810-23; PMID:10898795
   PubMed Web of Science ®Google Scholar
• Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007; 110:2067-74; PMID:17545502; http://dx.doi.org/10.1182/blood-2007-01-069575
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-5; PMID:20081860; http://dx.doi.org/10.1038/ng.518
   PubMed Web of Science ®Google Scholar
• Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14:155-64; PMID:15196462; http://dx.doi.org/10.1016/j.gde.2004.02.001
   PubMed Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23:677-92; PMID:23680150; http://dx.doi.org/10.1016/j.ccr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S, Brown R. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene 2013; 32:4586-92; PMID:23128397; http://dx.doi.org/10.1038/onc.2012.477
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108-12; PMID:23051747; http://dx.doi.org/10.1038/nature11606
   PubMed Web of Science ®Google Scholar
• Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, Hurov KE, Gygi SP, Colaiacovo MP, Elledge SJ. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A 2010; 107:18475-80; PMID:20937877; http://dx.doi.org/10.1073/pnas.1012946107
   PubMed Web of Science ®Google Scholar
• Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, McDowell ME, Wellman H, Tyler JK, Cairns BR, et al. HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget 2015; 6(7):4863-87.
   Web of Science ®Google Scholar
• Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013; 3:1002-19; PMID:23955273; http://dx.doi.org/10.1158/2159-8290.CD-13-0117
   PubMed Web of Science ®Google Scholar
• Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Mol Cell 2009; 36:110-20; PMID:19818714; http://dx.doi.org/10.1016/j.molcel.2009.08.019
   PubMed Web of Science ®Google Scholar
• Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol 2013; 33:845-57; PMID:23230272; http://dx.doi.org/10.1128/MCB.00990-12
   PubMed Web of Science ®Google Scholar
• Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, Mer G, Greenberg RA. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 2013; 20:317-25; PMID:23377543; http://dx.doi.org/10.1038/nsmb.2499
   PubMed Web of Science ®Google Scholar
• Ye J, Ai X, Eugeni EE, Zhang L, Carpenter LR, Jelinek MA, Freitas MA, Parthun MR. Histone H4 lysine 91 acetylation a core domain modification associated with chromatin assembly. Mol Cell 2005; 18:123-30; PMID:15808514; http://dx.doi.org/10.1016/j.molcel.2005.02.031
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature reviews. Genetics 2009; 10:32-42; PMID:19065135
   PubMed Web of Science ®Google Scholar
• Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, et al. SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. Mol Cell 2013; 51:454-68; PMID:23911928; http://dx.doi.org/10.1016/j.molcel.2013.06.018
   PubMed Web of Science ®Google Scholar
• Yuan Z, Seto E. A functional link between SIRT1 deacetylase and NBS1 in DNA damage response. Cell Cycle 2007; 6:2869-71; PMID:18156798; http://dx.doi.org/10.4161/cc.6.23.5026
   PubMed Web of Science ®Google Scholar
• Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH, Lee KH. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39:8-13; PMID:17334224; http://dx.doi.org/10.1038/emm.2007.2
   PubMed Web of Science ®Google Scholar
• Kaidi A, Weinert BT, Choudhary C, Jackson SP. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 2010; 329:1348-53; PMID:20829486; http://dx.doi.org/10.1126/science.1192049
   PubMed Web of Science ®Google Scholar
• Sims JK, Wade PA. Mi-2/NuRD complex function is required for normal S phase progression and assembly of pericentric heterochromatin. Mol Biol Cell 2011; 22:3094-102; PMID:21737684; http://dx.doi.org/10.1091/mbc.E11-03-0258
   PubMed Web of Science ®Google Scholar
• Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. The EMBO journal 2008; 27(7):1017-28; PMID:18354499; http://dx.doi.org/10.1038/emboj.2008.51
   PubMed Web of Science ®Google Scholar